| SC 13G/A | 2024-02-14 | RTW INVESTMENTS, LP | Fulcrum Therapeutics, Inc. | 5,469,956 | 8.8% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | Fulcrum Therapeutics, Inc. | 11,609,704 | 18.8% | EDGAR |
| SC 13G/A | 2024-02-14 | Third Rock Ventures III, L.P. | Fulcrum Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2024-02-13 | SUVRETTA CAPITAL MANAGEMENT, LLC | Fulcrum Therapeutics, Inc. | 5,518,881 | 8.9% | EDGAR |
| SC 13G/A | 2024-02-09 | FMR LLC | Fulcrum Therapeutics, Inc. | 5,684,615 | 9.2% | EDGAR |
| SC 13G/A | 2024-02-07 | ADAGE CAPITAL PARTNERS GP, L.L.C. | Fulcrum Therapeutics, Inc. | 1,506,422 | 2.4% | EDGAR |
| SC 13G/A | 2023-07-07 | BlackRock Inc. | Fulcrum Therapeutics, Inc. | 1,514,425 | 2.5% | EDGAR |
| SC 13G | 2023-03-06 | ADAGE CAPITAL PARTNERS GP, L.L.C. | Fulcrum Therapeutics, Inc. | 3,470,547 | 5.6% | EDGAR |
| SC 13G/A | 2023-02-14 | Point72 Asset Management, L.P. | Fulcrum Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2023-02-14 | RTW INVESTMENTS, LP | Fulcrum Therapeutics, Inc. | 4,993,279 | 9.6% | EDGAR |
| SC 13G/A | 2023-02-14 | Third Rock Ventures III, L.P. | Fulcrum Therapeutics, Inc. | 1,962,202 | 3.8% | EDGAR |
| SC 13G/A | 2023-02-13 | SUVRETTA CAPITAL MANAGEMENT, LLC | Fulcrum Therapeutics, Inc. | 4,274,803 | 8.2% | EDGAR |
| SC 13G/A | 2023-02-09 | FMR LLC | Fulcrum Therapeutics, Inc. | 5,233,725 | 10.1% | EDGAR |
| SC 13G/A | 2023-02-09 | ADAGE CAPITAL PARTNERS GP, L.L.C. | Fulcrum Therapeutics, Inc. | 1,120,000 | 2.2% | EDGAR |
| SC 13G/A | 2023-02-01 | BlackRock Inc. | Fulcrum Therapeutics, Inc. | 3,268,991 | 6.3% | EDGAR |
| SC 13G/A | 2023-01-23 | Cowen Financial Products LLC | Fulcrum Therapeutics, Inc. | 1,367,759 | 2.6% | EDGAR |
| SC 13G/A | 2023-01-06 | RA CAPITAL MANAGEMENT, L.P. | Fulcrum Therapeutics, Inc. | 9,686,628 | 18.6% | EDGAR |
| SC 13G | 2022-08-26 | RA CAPITAL MANAGEMENT, L.P. | Fulcrum Therapeutics, Inc. | 7,000,000 | 13.4% | EDGAR |
| SC 13G | 2022-06-22 | Point72 Asset Management, L.P. | Fulcrum Therapeutics, Inc. | 1,750,000 | 4.3% | EDGAR |
| SC 13G | 2022-03-10 | ADAGE CAPITAL PARTNERS GP, L.L.C. | Fulcrum Therapeutics, Inc. | 2,150,000 | 5.3% | EDGAR |